Despite the loss of the company’s COVID-19 antibody REGEN-COV earlier in 2022, Regeneron posted a positive first quarter driven primarily by sales of Dupixent and Eylea.
The U.S. Food and Drug Administration extended by three months the regulator agency’s review of Regeneron Pharmaceuticals Inc.’s application for full approval of the COVID-19 antibody therapy combination of casirivimab and imdevimab, the U.S. drugmaker said on April 14.
Although the COVID-19 pandemic has hit companies unevenly, some biopharma firms that have produced new drugs or vaccines against the disease have shown big spikes in drug sales. BioSpace reviewed five companies that produced non-vaccine treatments for COVID-19.
Regeneron Pharmaceuticals Inc. said on November 8 a single dose of the company’s antibody cocktail reduced the risk of contracting Covid-19 by 81.6 percent in a late-stage trial, in the two to eight months period following the drug’s administration.
The U.S. Food and Drug Administration agreed to place Regeneron Pharmaceuticals Inc.’s Biologics License Application (BLA) for the Covid-19 drug REGEN-COV under priority review with a target action date of April 13, 2022.
A World Health Organization (WHO) panel on Sept. 24 recommended the use of Regeneron and Roche’s Covid-19 antibody cocktail for patients at high risk of hospitalizations and those severely ill with no natural antibodies.
Eli Lilly said on Sept. 15 the U.S. government bought 388,000 additional doses of the company’s Covid-19 antibody therapy and Regeneron Pharmaceuticals said on Sept. 14 the U.S. government was buying 1.4 million additional doses of the Covid-19 antibody cocktail REGEN-COV., as infections surge due to the fast-spreading Delta variant.
